| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand Name | PF04383119 | |
| 3 | Generic Name | tanezumab | |
| 4 | Economics | Acquired from Rinat. | |
| 5 | Mechanism | Anti-NGF antibody | |
| 6 | Competition | REGN | |
| 7 | Clinical Trials | ||
| 8 | Phase III n=2500 CLBP | ||
| 9 | |||
| 10 | |||
| 11 | Phase II Osteoarthritis n=450 16-week | ||
| 12 | Side effects include parathesia, hypothesia, joint/extremity pain, peripheral edema. | ||
| 13 | S.S declines in pain versus placebo. ~50% decline in pain score from baseline vs 20% for placebo. |